Conference Coverage
Conference Coverage
Semaglutide beats canagliflozin as second-line therapy for type 2 diabetes
BARCELONA –
Conference Coverage
First data VERIFY value of early combination therapy in type 2 diabetes
BARCELONA –
Video
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug
Conference Coverage
Weight loss surgery linked to lower CV event risk in diabetes
Metabolic surgery was associated with a significantly lower cumulative incidence of myocardial infarction, ischemic stroke, and mortality than...
Conference Coverage
Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD
Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy.
News
Diabetic neuropathy: Often silent, often dangerous
Screening is crucial, but don’t forget about skin dryness, shoe fit, and more
Conference Coverage
Perils of ‘type’-casting: When adult-onset diabetes isn’t what you think it is
SAN DIEGO – There’s more to diabetes than type 1 and 2.
Conference Coverage
Urine albumin testing is crucial for patients at risk for CKD, but drop the 24-hour urine test
SAN DIEGO – An update on diagnosing, managing, and treating patients with comorbid hypertension and diabetes.
Conference Coverage
GLP-1 agonists, SGLT2 inhibitors offer more options in diabetes management
ORLANDO – “Finally, the ACC is aligned with the ADA. This is amazing, and it’s good news.” – Christine Kessler, MN
Conference Coverage
DECLARE-TIMI58 shows improved kidney function with dapagliflozin
SAN FRANCISCO – The SGLT2 dapagliflozin was better than placebo at slowing down kidney disease in patients with type 2 diabetes